[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBFNOtwgIKTATVaPmhljsthr1S-mcwIMgwjVq3CXPwrc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"Eastern Virginia Medical School",[4],56,false,6,5,6473,7,25,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Adherence, Medication",3,{"name":18,"count":16},"Sleep Apnea, Obstructive",{"name":20,"count":21},"Safety Issues",2,{"name":23,"count":21},"Pregestational Diabetes",{"name":25,"count":26},"Autonomic Nervous System Diseases",1,{"name":28,"count":26},"Sweat Gland Diseases",{"name":30,"count":26},"Diabetic Neuropathy With Neurologic Complication",{"name":32,"count":26},"Genital Human Papilloma Virus Infection",[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT04436081","Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease","2024-03","THC-free CBD Oil",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07124130","Lactated Ringer's and Dextrose 5% vs Only Lactated Ringer's in Labor","2026-03","5% Dextrose",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT07119398","Oxytocin\u002FFoley vs. Oxytocin for Induction in Patients With PPROM","2026-07-30","Oxytocin plus Foley Catheter",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07224893","Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management","2027-12-01","Use of insulin glargine once daily",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,86,104,127,145,167,185,208,235,260,286,312,338,363,392,410,428,446,474,499,528,546,573,591,619,637,655,681,705,732,757,781,806,833,851,875,900,926,948,974,998,1024],{"intervention":43,"totalTrials":26,"cells":63},{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":69,"PHASE3":71,"PHASE4":73,"NA":84},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[],{"trials":70,"activeCount":66},[],{"trials":72,"activeCount":66},[],{"trials":74,"activeCount":26,"soonestReadout":42},[75],{"nctId":40,"briefTitle":41,"status":76,"phases":77,"primaryCompletion":42,"completion":42,"start":78,"enrollment":79,"conditions":80,"interventions":82},"RECRUITING",[59],"2025-09",158,[81],"Induced Labor",[43,83],"Lactate Ringer",{"trials":85,"activeCount":66},[],{"intervention":83,"totalTrials":26,"cells":87},{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":96,"NA":102},{"trials":89,"activeCount":66},[],{"trials":91,"activeCount":66},[],{"trials":93,"activeCount":66},[],{"trials":95,"activeCount":66},[],{"trials":97,"activeCount":26,"soonestReadout":42},[98],{"nctId":40,"briefTitle":41,"status":76,"phases":99,"primaryCompletion":42,"completion":42,"start":78,"enrollment":79,"conditions":100,"interventions":101},[59],[81],[43,83],{"trials":103,"activeCount":66},[],{"intervention":48,"totalTrials":26,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":114,"NA":125},{"trials":107,"activeCount":66},[],{"trials":109,"activeCount":66},[],{"trials":111,"activeCount":66},[],{"trials":113,"activeCount":66},[],{"trials":115,"activeCount":26,"soonestReadout":47},[116],{"nctId":45,"briefTitle":46,"status":76,"phases":117,"primaryCompletion":47,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},[59],"2026-12-30","2025-07-14",80,[122],"Preterm PROM (Pregnancy)",[48,124],"Oxytocin",{"trials":126,"activeCount":66},[],{"intervention":124,"totalTrials":26,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":143},{"trials":130,"activeCount":66},[],{"trials":132,"activeCount":66},[],{"trials":134,"activeCount":66},[],{"trials":136,"activeCount":66},[],{"trials":138,"activeCount":26,"soonestReadout":47},[139],{"nctId":45,"briefTitle":46,"status":76,"phases":140,"primaryCompletion":47,"completion":118,"start":119,"enrollment":120,"conditions":141,"interventions":142},[59],[122],[48,124],{"trials":144,"activeCount":66},[],{"intervention":53,"totalTrials":26,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":165},{"trials":148,"activeCount":66},[],{"trials":150,"activeCount":66},[],{"trials":152,"activeCount":66},[],{"trials":154,"activeCount":66},[],{"trials":156,"activeCount":26,"soonestReadout":52},[157],{"nctId":50,"briefTitle":51,"status":76,"phases":158,"primaryCompletion":52,"completion":52,"start":159,"enrollment":160,"conditions":161,"interventions":163},[59],"2026-05-18",200,[23,162],"Pregnancy",[53,164],"Use of insulin glargine twice daily",{"trials":166,"activeCount":66},[],{"intervention":164,"totalTrials":26,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":183},{"trials":170,"activeCount":66},[],{"trials":172,"activeCount":66},[],{"trials":174,"activeCount":66},[],{"trials":176,"activeCount":66},[],{"trials":178,"activeCount":26,"soonestReadout":52},[179],{"nctId":50,"briefTitle":51,"status":76,"phases":180,"primaryCompletion":52,"completion":52,"start":159,"enrollment":160,"conditions":181,"interventions":182},[59],[23,162],[53,164],{"trials":184,"activeCount":66},[],{"intervention":38,"totalTrials":26,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":202,"PHASE4":204,"NA":206},{"trials":188,"activeCount":66},[],{"trials":190,"activeCount":66},[],{"trials":192,"activeCount":26,"soonestReadout":37},[193],{"nctId":35,"briefTitle":36,"status":76,"phases":194,"primaryCompletion":37,"completion":37,"start":195,"enrollment":196,"conditions":197,"interventions":201},[57],"2021-02-26",40,[198,199,200],"Alzheimer Disease","Dementia","Major Neurocognitive Disorder With Aggressive Behavior",[38],{"trials":203,"activeCount":66},[],{"trials":205,"activeCount":66},[],{"trials":207,"activeCount":66},[],{"intervention":209,"totalTrials":26,"cells":210},"omega-3-ethyl esters",{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":233},{"trials":212,"activeCount":66},[],{"trials":214,"activeCount":66},[],{"trials":216,"activeCount":66},[],{"trials":218,"activeCount":66},[],{"trials":220,"activeCount":66},[221],{"nctId":222,"briefTitle":223,"status":224,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":232},"NCT00931879","Lovaza® and Microvascular Function in Type 2 Diabetes","COMPLETED",[59],"2012-07","2009-10",44,[230,231],"Hypertriglyceridemia","Diabetic Neuropathy",[209],{"trials":234,"activeCount":66},[],{"intervention":236,"totalTrials":26,"cells":237},"Cycloset",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":258},{"trials":239,"activeCount":66},[],{"trials":241,"activeCount":66},[],{"trials":243,"activeCount":66},[],{"trials":245,"activeCount":66},[],{"trials":247,"activeCount":66},[248],{"nctId":249,"briefTitle":250,"status":224,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT02682901","Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects",[59],"2018-11-15","2015-10-05",84,[256],"Diabetic Autonomic Neuropathy",[236],{"trials":259,"activeCount":66},[],{"intervention":261,"totalTrials":26,"cells":262},"Gardasil-9",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":284},{"trials":264,"activeCount":66},[],{"trials":266,"activeCount":66},[],{"trials":268,"activeCount":66},[],{"trials":270,"activeCount":66},[],{"trials":272,"activeCount":66},[273],{"nctId":274,"briefTitle":275,"status":276,"phases":277,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT03350698","Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination","UNKNOWN",[59],"2023-12-30","2018-04-06",100,[282],"Papillomavirus Vaccines",[261],{"trials":285,"activeCount":66},[],{"intervention":287,"totalTrials":26,"cells":288},"Etonogestrel \u002FEthinyl Estradiol Contraceptive Vaginal Ring",{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":310},{"trials":290,"activeCount":66},[],{"trials":292,"activeCount":66},[],{"trials":294,"activeCount":66},[],{"trials":296,"activeCount":66},[],{"trials":298,"activeCount":66},[299],{"nctId":300,"briefTitle":301,"status":276,"phases":302,"primaryCompletion":303,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT01448291","Effect of the Etonogestrel 0.12mg\u002FEthinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers",[59],"2012-10","2013-03","2011-10",30,[308],"Vaginosis, Bacterial",[287],{"trials":311,"activeCount":66},[],{"intervention":313,"totalTrials":26,"cells":314},"Steroid\u002FAnesthesia Mixture",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":336},{"trials":316,"activeCount":66},[],{"trials":318,"activeCount":66},[],{"trials":320,"activeCount":66},[],{"trials":322,"activeCount":66},[],{"trials":324,"activeCount":66},[325],{"nctId":326,"briefTitle":327,"status":276,"phases":328,"primaryCompletion":329,"completion":329,"start":330,"enrollment":196,"conditions":331,"interventions":335},"NCT05292677","Laryngeal Nerve Block for Chronic Cough",[59],"2023-06-25","2021-07-21",[332,333,334],"Laryngeal Nerve Block","Chronic Neurogenic Cough","Laryngeal Hypersensitivity",[313],{"trials":337,"activeCount":66},[],{"intervention":339,"totalTrials":26,"cells":340},"Aspirin 81mg",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":361},{"trials":342,"activeCount":66},[],{"trials":344,"activeCount":66},[],{"trials":346,"activeCount":66},[],{"trials":348,"activeCount":66},[],{"trials":350,"activeCount":66},[351],{"nctId":352,"briefTitle":353,"status":276,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT04908982","Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension",[59],"2023-05-31","2021-05-28",60,[359],"Pre-Eclampsia",[339],{"trials":362,"activeCount":66},[],{"intervention":364,"totalTrials":26,"cells":365},"Copper IUD",{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":390},{"trials":367,"activeCount":66},[],{"trials":369,"activeCount":66},[],{"trials":371,"activeCount":66},[],{"trials":373,"activeCount":66},[],{"trials":375,"activeCount":66},[376],{"nctId":377,"briefTitle":378,"status":224,"phases":379,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":386},"NCT04814927","Impact of Contraceptives on Cervico-Vaginal Mucosa",[59],"2022-12-15","2021-03-01",112,[384,385],"Mucosal Inflammation","Contraceptive; Complications, Intrauterine",[364,387,388,389],"Etonogestrel implant","Levonorgestrel IUS","DMPA Sub-cutaneous",{"trials":391,"activeCount":66},[],{"intervention":387,"totalTrials":26,"cells":393},{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":402,"NA":408},{"trials":395,"activeCount":66},[],{"trials":397,"activeCount":66},[],{"trials":399,"activeCount":66},[],{"trials":401,"activeCount":66},[],{"trials":403,"activeCount":66},[404],{"nctId":377,"briefTitle":378,"status":224,"phases":405,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":406,"interventions":407},[59],[384,385],[364,387,388,389],{"trials":409,"activeCount":66},[],{"intervention":388,"totalTrials":26,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":426},{"trials":413,"activeCount":66},[],{"trials":415,"activeCount":66},[],{"trials":417,"activeCount":66},[],{"trials":419,"activeCount":66},[],{"trials":421,"activeCount":66},[422],{"nctId":377,"briefTitle":378,"status":224,"phases":423,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":424,"interventions":425},[59],[384,385],[364,387,388,389],{"trials":427,"activeCount":66},[],{"intervention":389,"totalTrials":26,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":444},{"trials":431,"activeCount":66},[],{"trials":433,"activeCount":66},[],{"trials":435,"activeCount":66},[],{"trials":437,"activeCount":66},[],{"trials":439,"activeCount":66},[440],{"nctId":377,"briefTitle":378,"status":224,"phases":441,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":442,"interventions":443},[59],[384,385],[364,387,388,389],{"trials":445,"activeCount":66},[],{"intervention":447,"totalTrials":26,"cells":448},"Pyridostigmine Bromide 60 Milligrams",{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":472},{"trials":450,"activeCount":66},[],{"trials":452,"activeCount":66},[],{"trials":454,"activeCount":66},[],{"trials":456,"activeCount":66},[],{"trials":458,"activeCount":66},[459],{"nctId":460,"briefTitle":461,"status":276,"phases":462,"primaryCompletion":463,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":471},"NCT05110417","Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine",[59],"2022-12-31","2023-06-01","2021-05-20",10,[468,469,470],"Dysphonia, Spastic","Dysphonia","Laryngeal Dystonia",[447],{"trials":473,"activeCount":66},[],{"intervention":475,"totalTrials":26,"cells":476},"Pregabalin",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":495,"NA":497},{"trials":478,"activeCount":66},[],{"trials":480,"activeCount":66},[],{"trials":482,"activeCount":66},[],{"trials":484,"activeCount":66},[485],{"nctId":486,"briefTitle":487,"status":224,"phases":488,"primaryCompletion":489,"completion":489,"start":490,"enrollment":228,"conditions":491,"interventions":494},"NCT02927951","The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy",[58],"2013-12","2011-01",[492,493],"Diabetic Peripheral Neuropathy","Nerve Pain",[475],{"trials":496,"activeCount":66},[],{"trials":498,"activeCount":66},[],{"intervention":500,"totalTrials":26,"cells":501},"Tranexamic Acid",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":524,"NA":526},{"trials":503,"activeCount":66},[],{"trials":505,"activeCount":66},[],{"trials":507,"activeCount":66},[],{"trials":509,"activeCount":66},[510],{"nctId":511,"briefTitle":512,"status":276,"phases":513,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":522},"NCT04311073","Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies",[58],"2024-07-30","2024-12-31","2020-06-20",50,[519,520,521],"Fibroid Uterus","Abnormal Uterine Bleeding","Myoma;Uterus",[500,523],"Placebos",{"trials":525,"activeCount":66},[],{"trials":527,"activeCount":66},[],{"intervention":523,"totalTrials":26,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":66},[],{"trials":533,"activeCount":66},[],{"trials":535,"activeCount":66},[],{"trials":537,"activeCount":66},[538],{"nctId":511,"briefTitle":512,"status":276,"phases":539,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":540,"interventions":541},[58],[519,520,521],[500,523],{"trials":543,"activeCount":66},[],{"trials":545,"activeCount":66},[],{"intervention":547,"totalTrials":26,"cells":548},"Fondaparinux",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":569,"NA":571},{"trials":550,"activeCount":66},[],{"trials":552,"activeCount":66},[],{"trials":554,"activeCount":66},[],{"trials":556,"activeCount":66},[557],{"nctId":558,"briefTitle":559,"status":560,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT00493896","Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients","TERMINATED",[58],"2010-04","2007-07",27,[566],"Venous Thromboembolism",[547,568],"Enoxaparin",{"trials":570,"activeCount":66},[],{"trials":572,"activeCount":66},[],{"intervention":568,"totalTrials":26,"cells":574},{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":587,"NA":589},{"trials":576,"activeCount":66},[],{"trials":578,"activeCount":66},[],{"trials":580,"activeCount":66},[],{"trials":582,"activeCount":66},[583],{"nctId":558,"briefTitle":559,"status":560,"phases":584,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":585,"interventions":586},[58],[566],[547,568],{"trials":588,"activeCount":66},[],{"trials":590,"activeCount":66},[],{"intervention":592,"totalTrials":26,"cells":593},"Progesterone Vaginal Gel 8%",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":615,"NA":617},{"trials":595,"activeCount":66},[],{"trials":597,"activeCount":66},[],{"trials":599,"activeCount":66},[],{"trials":601,"activeCount":66},[602],{"nctId":603,"briefTitle":604,"status":224,"phases":605,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":612},"NCT03440359","Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole",[57,58],"2016-11-02","2017-12-30","2012-07-06",52,[611],"Polycystic Ovary Syndrome",[592,613,614],"Letrozole Oral","Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe",{"trials":616,"activeCount":66},[],{"trials":618,"activeCount":66},[],{"intervention":613,"totalTrials":26,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":633,"NA":635},{"trials":622,"activeCount":66},[],{"trials":624,"activeCount":66},[],{"trials":626,"activeCount":66},[],{"trials":628,"activeCount":66},[629],{"nctId":603,"briefTitle":604,"status":224,"phases":630,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":631,"interventions":632},[57,58],[611],[592,613,614],{"trials":634,"activeCount":66},[],{"trials":636,"activeCount":66},[],{"intervention":614,"totalTrials":26,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":651,"NA":653},{"trials":640,"activeCount":66},[],{"trials":642,"activeCount":66},[],{"trials":644,"activeCount":66},[],{"trials":646,"activeCount":66},[647],{"nctId":603,"briefTitle":604,"status":224,"phases":648,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":649,"interventions":650},[57,58],[611],[592,613,614],{"trials":652,"activeCount":66},[],{"trials":654,"activeCount":66},[],{"intervention":656,"totalTrials":26,"cells":657},"3% oxybutynin",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":664,"PHASE4":677,"NA":679},{"trials":659,"activeCount":66},[],{"trials":661,"activeCount":66},[],{"trials":663,"activeCount":66},[],{"trials":665,"activeCount":66},[666],{"nctId":667,"briefTitle":668,"status":224,"phases":669,"primaryCompletion":670,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":676},"NCT03050827","Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy",[58],"2017-08-17","2017-12-31","2014-05-01",51,[675],"Diabetic; Neuropathic, Polyneuropathy (Manifestation)",[656],{"trials":678,"activeCount":66},[],{"trials":680,"activeCount":66},[],{"intervention":682,"totalTrials":26,"cells":683},"Liraglutide 6 mg Solution for",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":685,"activeCount":66},[],{"trials":687,"activeCount":66},[],{"trials":689,"activeCount":66},[690],{"nctId":691,"briefTitle":692,"status":276,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":228,"conditions":697,"interventions":698},"NCT03426085","The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes",[57],"2020-04","2020-08","2016-05",[25,28,30],[682],{"trials":700,"activeCount":66},[],{"trials":702,"activeCount":66},[],{"trials":704,"activeCount":66},[],{"intervention":706,"totalTrials":26,"cells":707},"Estradiol Transdermal Product",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":709,"activeCount":66},[],{"trials":711,"activeCount":66},[],{"trials":713,"activeCount":66},[714],{"nctId":715,"briefTitle":716,"status":276,"phases":717,"primaryCompletion":718,"completion":719,"start":720,"enrollment":466,"conditions":721,"interventions":725},"NCT03868202","Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol",[57],"2019-11","2020-01","2019-07-03",[722,723,724],"Follicle Stimulating Hormone Glycosylation","Urinary FSH21\u002FFSH24 Ratio","Estradiol Effect",[706],{"trials":727,"activeCount":66},[],{"trials":729,"activeCount":66},[],{"trials":731,"activeCount":66},[],{"intervention":733,"totalTrials":26,"cells":734},"IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":736,"activeCount":66},[],{"trials":738,"activeCount":66},[],{"trials":740,"activeCount":66},[741],{"nctId":742,"briefTitle":743,"status":224,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT01686503","Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects",[57],"2013-08","2012-09",231,[749],"Polio Immunity",[733],{"trials":752,"activeCount":66},[],{"trials":754,"activeCount":66},[],{"trials":756,"activeCount":66},[],{"intervention":758,"totalTrials":26,"cells":759},"Lisofylline",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":761,"activeCount":66},[],{"trials":763,"activeCount":66},[],{"trials":765,"activeCount":66},[766],{"nctId":767,"briefTitle":768,"status":560,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":26,"conditions":772,"interventions":774},"NCT01603121","Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus",[56,57],"2013-05","2012-02",[773],"Type 1 Diabetes Mellitus",[758],{"trials":776,"activeCount":66},[],{"trials":778,"activeCount":66},[],{"trials":780,"activeCount":66},[],{"intervention":782,"totalTrials":26,"cells":783},"Antimicrobial TheraGauze",{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":785,"activeCount":66},[],{"trials":787,"activeCount":66},[],{"trials":789,"activeCount":66},[790],{"nctId":791,"briefTitle":792,"status":224,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":8,"conditions":797,"interventions":799},"NCT02334384","Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess",[56,57],"2017-08-01","2017-08-30","2016-04-01",[798],"Furunculosis",[782],{"trials":801,"activeCount":66},[],{"trials":803,"activeCount":66},[],{"trials":805,"activeCount":66},[],{"intervention":807,"totalTrials":26,"cells":808},"emtricitabine\u002Ftenofovir alafenamide",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":810,"activeCount":66},[],{"trials":812,"activeCount":66},[],{"trials":814,"activeCount":66},[815],{"nctId":816,"briefTitle":817,"status":224,"phases":818,"primaryCompletion":819,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":825},"NCT05458765","Project Engage: Oral PrEP Acceptability",[57],"2023-12-13","2024-07-25","2022-06-21",330,[824,15],"Acceptability of Health Care",[807,826],"Emtricitabine \u002F Tenofovir Disoproxil Oral",{"trials":828,"activeCount":66},[],{"trials":830,"activeCount":66},[],{"trials":832,"activeCount":66},[],{"intervention":826,"totalTrials":26,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":836,"activeCount":66},[],{"trials":838,"activeCount":66},[],{"trials":840,"activeCount":66},[841],{"nctId":816,"briefTitle":817,"status":224,"phases":842,"primaryCompletion":819,"completion":820,"start":821,"enrollment":822,"conditions":843,"interventions":844},[57],[824,15],[807,826],{"trials":846,"activeCount":66},[],{"trials":848,"activeCount":66},[],{"trials":850,"activeCount":66},[],{"intervention":852,"totalTrials":26,"cells":853},"TAF\u002FEVG vaginal insert",{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":855,"activeCount":66},[],{"trials":857,"activeCount":66},[858],{"nctId":859,"briefTitle":860,"status":224,"phases":861,"primaryCompletion":862,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":866},"NCT06087913","Safety and PK Multi-dose Study of TAF\u002FEVG Vaginal Insert",[56],"2024-12-02","2023-11-08",68,[20],[852],{"trials":868,"activeCount":66},[],{"trials":870,"activeCount":66},[],{"trials":872,"activeCount":66},[],{"trials":874,"activeCount":66},[],{"intervention":876,"totalTrials":26,"cells":877},"TAF\u002FEVG rectal insert",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":879,"activeCount":66},[],{"trials":881,"activeCount":66},[882],{"nctId":883,"briefTitle":884,"status":224,"phases":885,"primaryCompletion":886,"completion":887,"start":888,"enrollment":889,"conditions":890,"interventions":891},"NCT06274398","Rectal Insert TAF\u002FEVG Pre-Exposure Prophylaxis (RITE PrEP) Study",[56],"2025-03-31","2025-05-16","2024-01-16",21,[20],[876],{"trials":893,"activeCount":66},[],{"trials":895,"activeCount":66},[],{"trials":897,"activeCount":66},[],{"trials":899,"activeCount":66},[],{"intervention":901,"totalTrials":26,"cells":902},"Tenofovir Disoproxil Fumarate\u002FEmtricitabine",{"EARLY_PHASE1":903,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":904,"activeCount":66},[905],{"nctId":906,"briefTitle":907,"status":224,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":912,"interventions":915},"NCT04870671","Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor",[55],"2023-01-31","2021-03-25",14,[913,15,914],"HIV\u002FAIDS","Drug Use",[901],{"trials":917,"activeCount":66},[],{"trials":919,"activeCount":66},[],{"trials":921,"activeCount":66},[],{"trials":923,"activeCount":66},[],{"trials":925,"activeCount":66},[],{"intervention":927,"totalTrials":26,"cells":928},"Gardasil",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":930,"activeCount":66},[],{"trials":932,"activeCount":66},[],{"trials":934,"activeCount":66},[],{"trials":936,"activeCount":66},[],{"trials":938,"activeCount":66},[],{"trials":940,"activeCount":66},[941],{"nctId":942,"briefTitle":943,"status":276,"phases":944,"primaryCompletion":746,"completion":303,"start":945,"enrollment":280,"conditions":946,"interventions":947},"NCT01133509","A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study",[60],"2009-09",[32],[927],{"intervention":949,"totalTrials":26,"cells":950},"Lisinopril",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":952,"activeCount":66},[],{"trials":954,"activeCount":66},[],{"trials":956,"activeCount":66},[],{"trials":958,"activeCount":66},[],{"trials":960,"activeCount":66},[],{"trials":962,"activeCount":66},[963],{"nctId":964,"briefTitle":965,"status":966,"phases":967,"primaryCompletion":968,"completion":968,"start":969,"enrollment":66,"conditions":970,"interventions":973},"NCT05016440","Lisinopril for Renal Protection in Postpartum Preeclamptic Women","WITHDRAWN",[60],"2015-09-01","2015-09",[971,972],"Microalbuminuria","Preeclampsia",[949],{"intervention":975,"totalTrials":26,"cells":976},"Acetylcysteine",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":978,"activeCount":66},[],{"trials":980,"activeCount":66},[],{"trials":982,"activeCount":66},[],{"trials":984,"activeCount":66},[],{"trials":986,"activeCount":66},[],{"trials":988,"activeCount":66},[989],{"nctId":990,"briefTitle":991,"status":276,"phases":992,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT00396396","Role of Acetylcysteine in Creatinine Clearance",[60],"2006-10",35,[996],"Creatinine Clearance",[975],{"intervention":999,"totalTrials":26,"cells":1000},"Antibiotics",{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":1002,"activeCount":66},[],{"trials":1004,"activeCount":66},[],{"trials":1006,"activeCount":66},[],{"trials":1008,"activeCount":66},[],{"trials":1010,"activeCount":66},[],{"trials":1012,"activeCount":66},[1013],{"nctId":1014,"briefTitle":1015,"status":276,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT05328817","Azithromycin Versus Erythromycin For Preterm Prelabor Rupture of Membranes",[60],"2025-05-01","2025-07-01","2022-05-01",240,[1022],"Preterm Premature Rupture of Membrane",[999],{"intervention":1025,"totalTrials":26,"cells":1026},"Niacin and aspirin",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1028,"activeCount":66},[],{"trials":1030,"activeCount":66},[],{"trials":1032,"activeCount":66},[],{"trials":1034,"activeCount":66},[],{"trials":1036,"activeCount":66},[],{"trials":1038,"activeCount":66},[1039],{"nctId":1040,"briefTitle":1041,"status":224,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":306,"conditions":1045,"interventions":1047},"NCT00930839","Role of Prostaglandins on Niacin-Induced Flushing",[],"2010-02","2009-03",[1046],"Flushing",[1025]]